Browse by Audience
MEMBER

Update Your Profile
Member Spotlights
Refer a Member: IASP Champions
Join a Special Interest Group (SIG)
Find a Chapter
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Papers of the Week
Webinars and Podcasts
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Webinars & Podcasts
Curricula
Graduate Opportunities
Events

PATIENT & CAREGIVER

RELIEF News
Resources for Living with Pain
Global Alliance of Partners in Pain Advocacy (GAPPA)
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner

gy2022-1-3
I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Evaluating rimegepant for the treatment of migraine.

< BACK TO ARCHIVE


Papers: 27 Feb 2021 - 5 Mar 2021


Pharmacology/Drug Development

PAIN TYPE:
Migraine/Headache


2021 Mar 01


Expert Opin Pharmacother


http://www.ncbi.nlm.nih.gov/pubmed/33648385?dopt=Abstract

Evaluating rimegepant for the treatment of migraine.

Authors

Evaluating rimegepant for the treatment of migraine.
de Vries T, Al-Hassany L, Maassen Van Den Brink A
Expert Opin Pharmacother. 2021 Mar 01.
PMID: 33648385.

Abstract

Calcitonin gene-related peptide (CGRP) is a vasodilatory neuropeptide that plays an essential role in the pathophysiology of migraine, a highly disabling neurovascular disorder characterized by severe headache attacks. Rimegepant is a small-molecule CGRP receptor antagonist that is approved by the FDA for the acute treatment of migraine and currently under investigation for migraine prophylaxis.
Read This Paper